Suppr超能文献

肝细胞癌的联合介入治疗

Combined interventional therapies of hepatocellular carcinoma.

作者信息

Qian Jun, Feng Gan-Sheng, Vogl Thomas

机构信息

Department of Radiology, Xiehe Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China.

出版信息

World J Gastroenterol. 2003 Sep;9(9):1885-91. doi: 10.3748/wjg.v9.i9.1885.

Abstract

Hepatocellular carcinoma (HCC) is one of the most common malignancies in the world, responsible for an estimated one million deaths annually. It has a poor prognosis due to its rapid infiltrating growth and complicating liver cirrhosis. Surgical resection, liver transplantation and cryosurgery are considered the best curative options, achieving a high rate of complete response, especially in patients with small HCC and good residual liver function. In nonsurgery, regional interventional therapies have led to a major breakthrough in the management of unresectable HCC, which include transarterial chemoembolization (TACE), percutaneous ethanol injection (PEI), radiofrequency ablation (RFA), microwave coagulation therapy (MCT), laser-induced thermotherapy (LITT), etc. As a result of the technical development of locoregional approaches for HCC during the recent decades, the range of combined interventional therapies has been continuously extended. Most combined multimodal interventional therapies reveal their enormous advantages as compared with any single therapeutic regimen alone, and play more important roles in treating unresectable HCC.

摘要

肝细胞癌(HCC)是世界上最常见的恶性肿瘤之一,每年估计导致100万人死亡。由于其浸润性生长迅速且常并发肝硬化,预后较差。手术切除、肝移植和冷冻手术被认为是最佳的治愈选择,能实现较高的完全缓解率,尤其是在小肝癌且残余肝功能良好的患者中。在非手术治疗方面,区域介入治疗在不可切除HCC的管理上取得了重大突破,包括经动脉化疗栓塞术(TACE)、经皮乙醇注射(PEI)、射频消融(RFA)、微波凝固治疗(MCT)、激光诱导热疗(LITT)等。由于近几十年来HCC局部区域治疗方法的技术发展,联合介入治疗的范围不断扩大。与任何单一治疗方案相比,大多数联合多模式介入治疗都显示出巨大优势,在治疗不可切除HCC中发挥着更重要的作用。

相似文献

1
Combined interventional therapies of hepatocellular carcinoma.
World J Gastroenterol. 2003 Sep;9(9):1885-91. doi: 10.3748/wjg.v9.i9.1885.
2
Interventional therapies of unresectable liver metastases.
J Cancer Res Clin Oncol. 2011 Dec;137(12):1763-72. doi: 10.1007/s00432-011-1026-9. Epub 2011 Sep 11.
3
Interventional radiology for hepatocellular carcinoma.
Minerva Gastroenterol Dietol. 2011 Sep;57(3):299-309.
5
Interventional treatments for hepatocellular carcinoma.
Hepatobiliary Pancreat Dis Int. 2006 Nov;5(4):495-500.
8
Outcome of regional and local ablative therapies for hepatocellular carcinoma: a collective review.
Eur J Surg Oncol. 2005 May;31(4):331-47. doi: 10.1016/j.ejso.2004.10.011.
10
Localized hepatocellular carcinoma: therapeutic options.
Curr Gastroenterol Rep. 2000 Feb;2(1):72-81. doi: 10.1007/s11894-000-0054-4.

引用本文的文献

2
Experimental Study on Evaluation of Blood Supply Level and Embolization Ratio of Liver Cancer Based on I-Flow Software.
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820970665. doi: 10.1177/1533033820970665.
4
Glycyrrhetinic acid-functionalized mesoporous silica nanoparticles as hepatocellular carcinoma-targeted drug carrier.
Int J Nanomedicine. 2017 Jun 12;12:4361-4370. doi: 10.2147/IJN.S135626. eCollection 2017.
5
Association of hepatic vein Lipiodol tram-track sign during transcatheter arterial chemoembolization with perioperative death.
J Int Med Res. 2017 Jun;45(3):1148-1157. doi: 10.1177/0300060517704141. Epub 2017 Apr 20.
9
Hypoxia-activated cytotoxic agent tirapazamine enhances hepatic artery ligation-induced killing of liver tumor in HBx transgenic mice.
Proc Natl Acad Sci U S A. 2016 Oct 18;113(42):11937-11942. doi: 10.1073/pnas.1613466113. Epub 2016 Oct 4.

本文引用的文献

8
Clinical short-term results of radiofrequency ablation in liver cancers.
World J Gastroenterol. 2002 Aug;8(4):624-30. doi: 10.3748/wjg.v8.i4.624.
10
Locoregional immunochemotherapy in hepatocellular carcinoma.
Hepatogastroenterology. 2002 Jul-Aug;49(46):1109-12.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验